These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 24589363)

  • 61. Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
    Collier D; Iwuji C; Derache A; de Oliveira T; Okesola N; Calmy A; Dabis F; Pillay D; Gupta RK;
    Clin Infect Dis; 2017 Apr; 64(8):1006-1016. PubMed ID: 28329393
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.
    Hafkin JS; Osborn MK; Localio AR; Amorosa VK; Kostman JR; Stern JJ; De La Torre P; Mounzer K; Frank I; Gross R; Chang KM; Lo Re V
    J Viral Hepat; 2014 Apr; 21(4):288-96. PubMed ID: 24597697
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
    Manfredi R; Calza L
    AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/ emtricitabine in antiretroviral-naïve subjects: the progress study, 48-week results.
    Reynes J; Lawal A; Pulido F; Soto-Malave R; Gathe J; Tian M; Fredrick LM; Podsadecki TJ; Nilius AM
    HIV Clin Trials; 2011; 12(5):255-67. PubMed ID: 22180523
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Substituting Abacavir for Stavudine in Children Who Are Virally Suppressed Without Lipodystrophy: Randomized Clinical Trial in Johannesburg, South Africa.
    Strehlau R; Shiau S; Arpadi S; Patel F; Pinillos F; Tsai WY; Coovadia A; Abrams E; Kuhn L
    J Pediatric Infect Dis Soc; 2018 Aug; 7(3):e70-e77. PubMed ID: 29373687
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Tenofovir: a nucleotide analog for the management of human immunodeficiency virus infection.
    Antoniou T; Park-Wyllie LY; Tseng AL
    Pharmacotherapy; 2003 Jan; 23(1):29-43. PubMed ID: 12523458
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.
    Ferrer E; Gatell JM; Sanchez P; Domingo P; Puig T; Niubo J; Cortes C; Veloso S; Pedrol E; Leon A; Gutierrez M; Podzamczer D
    AIDS Res Hum Retroviruses; 2008 Jul; 24(7):931-4. PubMed ID: 18671476
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis.
    Technau KG; Schomaker M; Kuhn L; Moultrie H; Coovadia A; Eley B; Rabie H; Wood R; Cox V; Vizcaya LS; Muchiri E; Davies MA;
    Pediatr Infect Dis J; 2014 Jun; 33(6):617-22. PubMed ID: 24378944
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Timing of pregnancy, postpartum risk of virologic failure and loss to follow-up among HIV-positive women.
    Onoya D; Sineke T; Brennan AT; Long L; Fox MP
    AIDS; 2017 Jul; 31(11):1593-1602. PubMed ID: 28463877
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Changes in elevated cholesterol in the era of tenofovir in South Africa: risk factors, clinical management and outcomes.
    Jamieson L; Evans D; Brennan AT; Moyo F; Spencer D; Mahomed K; Maskew M; Long L; Rosen S; Fox MP
    HIV Med; 2017 Sep; 18(8):595-603. PubMed ID: 28332270
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Rilpivirine versus efavirenz with emtricitabine/tenofovir disoproxil fumarate in treatment-naïve HIV-1-infected patients with HIV-1 RNA ≤100,000 copies/mL: week 96 pooled ECHO/THRIVE subanalysis.
    Behrens G; Rijnders B; Nelson M; Orkin C; Cohen C; Mills A; Elion RA; Vanveggel S; Stevens M; Rimsky L; Thorpe D; Bosse M; White K; Zhong L; DeMorin J; Chuck SK
    AIDS Patient Care STDS; 2014 Apr; 28(4):168-75. PubMed ID: 24660840
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.
    Chi BH; Mwango A; Giganti MJ; Sikazwe I; Moyo C; Schuttner L; Mulenga LB; Bolton-Moore C; Chintu NT; Sheneberger R; Stringer EM; Stringer JS
    J Acquir Immune Defic Syndr; 2011 Dec; 58(5):475-81. PubMed ID: 21857354
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.
    Wirden M; Marcelin AG; Tubiana R; Valantin MA; Ghosn J; Duvivier C; Dominguez S; Paris L; Agher R; Peytavin G; Katlama C; Calvez V
    J Acquir Immune Defic Syndr; 2004 Jul; 36(3):876-8. PubMed ID: 15213573
    [No Abstract]   [Full Text] [Related]  

  • 74. Reasons for first line ART modification over the years during the ART scale up in Uganda.
    Castelnuovo B; Mubiru F; Kalule I; Kiragga A
    AIDS Res Ther; 2019 Oct; 16(1):31. PubMed ID: 31597561
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Stavudine toxicity in women is the main reason for treatment change in a 3-year prospective cohort of adult patients started on first-line antiretroviral treatment in Uganda.
    Castelnuovo B; Kiragga A; Kamya MR; Manabe Y
    J Acquir Immune Defic Syndr; 2011 Jan; 56(1):59-63. PubMed ID: 20861741
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia.
    Mulenga L; Musonda P; Mwango A; Vinikoor MJ; Davies MA; Mweemba A; Calmy A; Stringer JS; Keiser O; Chi BH; Wandeler G;
    Clin Infect Dis; 2014 May; 58(10):1473-80. PubMed ID: 24585558
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Improved lipid profiles and maintenance of virologic control in heavily pretreated HIV-infected patients who switched from stavudine to tenofovir treatment.
    Schewe CK; Maserati R; Wassmer G; Adam A; Weitner L
    Clin Infect Dis; 2006 Jan; 42(1):145-7. PubMed ID: 16323105
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.
    Hamers RL; Sigaloff KC; Wensing AM; Wallis CL; Kityo C; Siwale M; Mandaliya K; Ive P; Botes ME; Wellington M; Osibogun A; Stevens WS; Rinke de Wit TF; Schuurman R;
    Clin Infect Dis; 2012 Jun; 54(11):1660-9. PubMed ID: 22474222
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues.
    Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C
    HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Tuberculosis treatment and risk of stavudine substitution in first-line antiretroviral therapy.
    Westreich DJ; Sanne I; Maskew M; Malope-Kgokong B; Conradie F; Majuba P; Funk MJ; Kaufman JS; Van Rie A; Macphail P
    Clin Infect Dis; 2009 Jun; 48(11):1617-23. PubMed ID: 19385733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.